tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Bhatia M et al. | An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. | 2010 | Biol. Blood Marrow Transplant. | pmid:19835971 |
| Devine SM et al. | The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis. | 1997 | Biol. Blood Marrow Transplant. | pmid:9209738 |
| Ohata K et al. | Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen. | 2011 | Biol. Blood Marrow Transplant. | pmid:20736080 |
| Kolb M et al. | Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation. | 2016 | Biol. Blood Marrow Transplant. | pmid:26880117 |
| Koreth J et al. | A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. | 2015 | Biol. Blood Marrow Transplant. | pmid:26055298 |
| Klein OR et al. | Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders. | 2016 | Biol. Blood Marrow Transplant. | pmid:26860634 |
| Kennedy-Nasser AA et al. | Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. | 2006 | Biol. Blood Marrow Transplant. | pmid:17162209 |
| Kusumi E et al. | Hepatic injury following reduced intensity unrelated cord blood transplantation for adult patients with hematological diseases. | 2006 | Biol. Blood Marrow Transplant. | pmid:17162212 |
| Chen YB et al. | Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. | 2015 | Biol. Blood Marrow Transplant. | pmid:26009261 |
| Kebriaei P et al. | Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. | 2009 | Biol. Blood Marrow Transplant. | pmid:19539211 |
| Ho VT et al. | Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. | 2009 | Biol. Blood Marrow Transplant. | pmid:19539216 |
| Osunkwo I et al. | A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. | 2004 | Biol. Blood Marrow Transplant. | pmid:15077223 |
| Yahng SA et al. | A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia. | 2015 | Biol. Blood Marrow Transplant. | pmid:25300871 |
| Horowitz MM et al. | Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. | 1999 | Biol. Blood Marrow Transplant. | pmid:10392964 |
| Cutler C et al. | Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. | 2005 | Biol. Blood Marrow Transplant. | pmid:15846292 |
| Tomblyn MR et al. | Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. | 2011 | Biol. Blood Marrow Transplant. | pmid:21073974 |
| Park SS et al. | Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate. | 2017 | Biol. Blood Marrow Transplant. | pmid:28554856 |
| Openshaw H | Peripheral neuropathy after bone marrow transplantation. | 1997 | Biol. Blood Marrow Transplant. | pmid:9360782 |
| Baird K et al. | Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. | 2015 | Biol. Blood Marrow Transplant. | pmid:25771402 |
| Yagasaki H et al. | Tacrolimus/Methotrexate versus cyclosporine/methotrexate as graft-versus-host disease prophylaxis in patients with severe aplastic anemia who received bone marrow transplantation from unrelated donors: results of matched pair analysis. | 2009 | Biol. Blood Marrow Transplant. | pmid:19896085 |
| Carnevale-Schianca F et al. | Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. | 2000 | Biol. Blood Marrow Transplant. | pmid:11128811 |
| Vasu S et al. | Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease. | 2016 | Biol. Blood Marrow Transplant. | pmid:26743340 |
| Satwani P et al. | A Phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen. | 2012 | Biol. Blood Marrow Transplant. | pmid:22079471 |
| Treister N et al. | An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. | 2016 | Biol. Blood Marrow Transplant. | pmid:27590106 |
| Sabry W et al. | Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. | 2009 | Biol. Blood Marrow Transplant. | pmid:19589481 |
| Burroughs LM et al. | Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial. | 2014 | Biol. Blood Marrow Transplant. | pmid:25196857 |
| Kanate AS et al. | Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. | 2017 | Biol. Blood Marrow Transplant. | pmid:28412518 |
| Pavletic S and Vogelsand GB | Treatment of high-risk chronic GVHD. | 2008 | Biol. Blood Marrow Transplant. | pmid:19041069 |
| Piñana JL et al. | A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis. | 2017 | Biol. Blood Marrow Transplant. | pmid:28396159 |
| Rosenbeck LL et al. | Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation. | 2011 | Biol. Blood Marrow Transplant. | pmid:20932925 |
| Carmona A et al. | Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide. | 2013 | Biol. Blood Marrow Transplant. | pmid:23845694 |
| Oran B et al. | Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. | 2007 | Biol. Blood Marrow Transplant. | pmid:17382253 |
| Cutler C et al. | Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. | 2004 | Biol. Blood Marrow Transplant. | pmid:15111932 |
| Cutler C et al. | Generic immunosuppressants in hematopoietic cell transplantation. | 2011 | Biol. Blood Marrow Transplant. | pmid:21087678 |
| Ram R et al. | Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. | 2012 | Biol. Blood Marrow Transplant. | pmid:21875504 |
| Leather H et al. | Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. | 2006 | Biol. Blood Marrow Transplant. | pmid:16503502 |
| Solomon SR et al. | Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. | 2015 | Biol. Blood Marrow Transplant. | pmid:25797174 |
| Grossman J et al. | Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. | 2014 | Biol. Blood Marrow Transplant. | pmid:25111582 |
| Luznik L et al. | HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. | 2008 | Biol. Blood Marrow Transplant. | pmid:18489989 |
| Snyder DS et al. | Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. | 2010 | Biol. Blood Marrow Transplant. | pmid:19786111 |
| Hamilton BK and Kalaycio M | Maximizing the benefits of mycophenolate mofetil as graft-versus-host disease prophylaxis. | 2014 | Biol. Blood Marrow Transplant. | pmid:25065905 |
| Narimatsu H et al. | Early central nervous complications after umbilical cord blood transplantation for adults. | 2009 | Biol. Blood Marrow Transplant. | pmid:19135947 |
| Platzbecker U et al. | Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. | 2009 | Biol. Blood Marrow Transplant. | pmid:19135948 |
| Wolff D et al. | Sirolimus in combination with tacrolimus in allogeneic stem cell transplantation--timing and conditioning regimen may be crucial. | 2008 | Biol. Blood Marrow Transplant. | pmid:18640579 |
| Shayani S et al. | Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis. | 2013 | Biol. Blood Marrow Transplant. | pmid:23078784 |
| Mori T et al. | Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors. | 2012 | Biol. Blood Marrow Transplant. | pmid:21708109 |
| Nieto Y et al. | Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. | 2006 | Biol. Blood Marrow Transplant. | pmid:16443519 |
| Uberti JP et al. | Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. | 2005 | Biol. Blood Marrow Transplant. | pmid:16125638 |
| Perkins J et al. | A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. | 2010 | Biol. Blood Marrow Transplant. | pmid:20102746 |
| Kumar AJ et al. | Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation. | 2013 | Biol. Blood Marrow Transplant. | pmid:23635453 |
| Miyakoshi S et al. | Invasive fungal infection following reduced-intensity cord blood transplantation for adult patients with hematologic diseases. | 2007 | Biol. Blood Marrow Transplant. | pmid:17580255 |
| Goyal RK et al. | Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. | 2013 | Biol. Blood Marrow Transplant. | pmid:23266742 |
| Al-Kadhimi Z et al. | Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation. | 2012 | Biol. Blood Marrow Transplant. | pmid:22710143 |
| Przepiorka D et al. | Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. | 1999 | Biol. Blood Marrow Transplant. | pmid:10371361 |
| Przepiorka D et al. | Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. | 2000 | Biol. Blood Marrow Transplant. | pmid:10816027 |
| Cuellar-Rodriguez J et al. | Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency. | 2015 | Biol. Blood Marrow Transplant. | pmid:25636378 |
| Wingard JR et al. | Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. | 1998 | Biol. Blood Marrow Transplant. | pmid:9923414 |
| Andersson BS et al. | Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. | 2011 | Biol. Blood Marrow Transplant. | pmid:20946966 |
| Ogawa H et al. | Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. | 2006 | Biol. Blood Marrow Transplant. | pmid:17084371 |
| Khaled SK et al. | Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. | 2016 | Biol. Blood Marrow Transplant. | pmid:26325438 |
| Satwani P et al. | Risk factors associated with kidney injury and the impact of kidney injury on overall survival in pediatric recipients following allogeneic stem cell transplant. | 2011 | Biol. Blood Marrow Transplant. | pmid:21338706 |
| Carnevale-Schianca F et al. | Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. | 2017 | Biol. Blood Marrow Transplant. | pmid:28039079 |
| Inamoto Y et al. | A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. | 2011 | Biol. Blood Marrow Transplant. | pmid:21421070 |
| Offer K et al. | Efficacy of tacrolimus/mycophenolate mofetil as acute graft-versus-host disease prophylaxis and the impact of subtherapeutic tacrolimus levels in children after matched sibling donor allogeneic hematopoietic cell transplantation. | 2015 | Biol. Blood Marrow Transplant. | pmid:25536217 |
| Aldoss I et al. | Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. | 2016 | Biol. Blood Marrow Transplant. | pmid:27044907 |
| Furlong T et al. | Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. | 2008 | Biol. Blood Marrow Transplant. | pmid:18410895 |
| Kim HJ et al. | Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. | 2009 | Biol. Blood Marrow Transplant. | pmid:19450755 |
| Small TN et al. | Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. | 2007 | Biol. Blood Marrow Transplant. | pmid:17241929 |
| Carnevale-Schianca F et al. | Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study. | 2009 | Biol. Blood Marrow Transplant. | pmid:19450760 |
| Santarone S et al. | Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia. | 2011 | Biol. Blood Marrow Transplant. | pmid:21385623 |
| Al-Kadhimi Z et al. | High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients. | 2014 | Biol. Blood Marrow Transplant. | pmid:24709007 |
| Gladstone DE et al. | Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. | 2013 | Biol. Blood Marrow Transplant. | pmid:23353119 |
| Socié G | Graft-versus-host disease prophylaxis: does drug dosage matter? | 2012 | Biol. Blood Marrow Transplant. | pmid:22200648 |
| Moiseev IS et al. | Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil. | 2016 | Biol. Blood Marrow Transplant. | pmid:26970381 |
| Hamadani M et al. | Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. | 2009 | Biol. Blood Marrow Transplant. | pmid:19822302 |
| Inamoto Y et al. | Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. | 2015 | Biol. Blood Marrow Transplant. | pmid:26033280 |
| Cadou A et al. | The Kin1 kinase and the calcineurin phosphatase cooperate to link actin ring assembly and septum synthesis in fission yeast. | 2013 | Biol. Cell | pmid:23294323 |
| Homma M et al. | False positive blood tacrolimus concentration in microparticle enzyme immunoassay. | 2002 | Biol. Pharm. Bull. | pmid:12186423 |
| Hazama Y et al. | Effect of Physiological Changes in the Skin on Systemic Absorption of Tacrolimus Following Topical Application in Rats. | 2016 | Biol. Pharm. Bull. | pmid:26934927 |
| Takeuchi H et al. | Evidence of different pharmacokinetics including relationship among AUC, peak, and trough levels between cyclosporine and tacrolimus in renal transplant recipients using new pharmacokinetic parameter--why cyclosporine is monitored by C(2) level and tacrolimus by trough level--. | 2008 | Biol. Pharm. Bull. | pmid:18175948 |
| Zhu Y et al. | Participation of proteinase-activated receptor-2 in passive cutaneous anaphylaxis-induced scratching behavior and the inhibitory effect of tacrolimus. | 2009 | Biol. Pharm. Bull. | pmid:19571380 |
| Kawazoe H et al. | Change of the blood concentration of tacrolimus after the switch from fluconazole to voriconazole in patients receiving allogeneic hematopoietic stem cell transplantation. | 2006 | Biol. Pharm. Bull. | pmid:17142996 |
| Uesugi M et al. | Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients. | 2013 | Biol. Pharm. Bull. | pmid:24189425 |
| Takeuchi H et al. | Steroid withdrawal based on lymphocyte sensitivity to endogenous steroid in renal transplant recipients. | 2011 | Biol. Pharm. Bull. | pmid:21963498 |
| Okada Y et al. | Tacrolimus ameliorates dextran sulfate sodium-induced colitis in mice: implication of interferon-γ and interleukin-1β suppression. | 2011 | Biol. Pharm. Bull. | pmid:22130237 |
| Sasa H et al. | Hepatic extraction of tacrolimus in rats with experimental liver diseases. | 1998 | Biol. Pharm. Bull. | pmid:9657047 |
| Quezada CA et al. | Effect of tacrolimus on activity and expression of P-glycoprotein and ATP-binding cassette transporter A5 (ABCA5) proteins in hematoencephalic barrier cells. | 2008 | Biol. Pharm. Bull. | pmid:18827354 |
| Tomita T et al. | Use of sample hematocrit value to correct blood tacrolimus concentration derived by microparticle enzyme immunoassay. | 2008 | Biol. Pharm. Bull. | pmid:18520063 |
| Matsui K et al. | Betamethasone, but Not Tacrolimus, Suppresses the Development of Th2 Cells Mediated by Langerhans Cell-Like Dendritic Cells. | 2016 | Biol. Pharm. Bull. | pmid:27374298 |
| Naito T et al. | Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. | 2006 | Biol. Pharm. Bull. | pmid:16462031 |
| Naito T et al. | Influence of metal cations on plasma trough concentration of mycophenolic Acid and its glucuronide in tacrolimus-treated and cyclosporine-treated kidney transplant recipients. | 2008 | Biol. Pharm. Bull. | pmid:18520072 |
| Sakai M et al. | Increased bioavailability of tacrolimus after rectal administration in rats. | 2004 | Biol. Pharm. Bull. | pmid:15340245 |
| Minematsu T et al. | Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs. | 1999 | Biol. Pharm. Bull. | pmid:10746167 |
| Yamaguchi K et al. | Limited sampling strategy for the estimation of mycophenolic acid area under the concentration-time curve treated in Japanese living-related renal transplant recipients with concomitant extended-release tacrolimus. | 2013 | Biol. Pharm. Bull. | pmid:23558676 |
| Nakano T et al. | Effects of topical application of tacrolimus on acute itch-associated responses in mice. | 2008 | Biol. Pharm. Bull. | pmid:18379077 |
| Kinugasa F et al. | Effect of a new immunosuppressant histon deacetylase (HDAC) inhibitor FR276457 in a rat cardiac transplant model. | 2008 | Biol. Pharm. Bull. | pmid:18758066 |
| Tanaka S et al. | P-glycoprotein function in peripheral blood mononuclear cells of myasthenia gravis patients treated with tacrolimus. | 2007 | Biol. Pharm. Bull. | pmid:17268068 |
| Noto T et al. | Tacrolimus (FK506) limits accumulation of granulocytes and platelets and protects against brain damage after transient focal cerebral ischemia in rat. | 2007 | Biol. Pharm. Bull. | pmid:17268072 |
| Mahakunakorn P et al. | Cytoprotective and cytotoxic effects of curcumin: dual action on H2O2-induced oxidative cell damage in NG108-15 cells. | 2003 | Biol. Pharm. Bull. | pmid:12736521 |
| Shimoeda S et al. | Analysis of the blood level of micafungin involving patients with hematological diseases: new findings regarding combination therapy with tacrolimus. | 2005 | Biol. Pharm. Bull. | pmid:15744072 |